Completing data — refresh the page later to see the latest
1642581-63-2Cn1cc(-c2cnc3cnn(S(=O)(=O)c4cnc5ccc(-c6cnn(C)c6)cn45)c3c2)cn1RYBLECYFLJXEJX-UHFFFAOYSA-N1642581-63-2DTXSID601375585CHEMBL4594400Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
DescriptionGlumetinib (1642581-63-2) is a highly selective (2400-fold selectivity against a panel of 312 kinases) and potent (IC50 = 0.42 nM) inhibitor of c-Met kinase. It induced tumor regression in MET-driven CDX (MKN-45, SNU-5, EBC-1) and PDX (4 NSCLC, 5 HCC) tumor models.
UsesGlumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor with an IC50 of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity[1].